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Inborn errors resulting in isolated functional methionine synthase deficiency fall into two complementation
groups, cblG and cblE. Using biochemical approaches we demonstrate that one cblG patient has greatly reduced
levels of methionine synthase while in another, the enzyme is specifically impaired in the reductive activation
cycle. The biochemical data suggested that low levels of methionine synthase activity in the first patient may
result from mutations in the catalytic domains of the enzyme, reduced transcription, or generation of unstable
message or protein. Using Northern analysis, we demonstrate that the molecular basis for the biochemical
phenotype in this patient is associated with greatly diminished steady-state levels of methionine synthase mRNA.
The biochemical data on the second patient cell line implicated mutations specific to reductive activation, a
function that is housed in the C-terminal AdoMet-binding domain and the intermediate B12-binding domain, in the
highly homologous bacterial enzyme. We have detected two mutations in a compound heterozygous state, one
that results in conversion of a conserved proline (1173) to a leucine residue and the other a deletion of an
isoleucine residue (881). The crystal structure of the C-terminal domain of the Escherichia coli MS predicts that
the Pro to Leu mutation could disrupt activation since it is embedded in a sequence that makes direct contacts
with the bound AdoMet. Deletion of isoleucine in the B12-binding domain would result in shortening of a β-sheet.
Our data provide the first evidence for mutations in the methionine synthase gene being culpable for the cblG
phenotype. In addition, they suggest directly that mutations in methionine synthase can lead to elevated
homocysteine, implicated both in neural tube defects and in cardiovascular diseases.
INTRODUCTION
Cobalamin is an organometallic cofactor required by only two
known enzymes in mammals (1,2). Intracellular cobalamin
metabolism is complex, compartmentalized, and requires the
interplay of a variety of gene products. In the mitochondrion, the
processing pathway leads to adenosylcobalamin (AdoCbl),
whereas the cytoplasmic route leads to methylcobalamin (MeCbl).
In both compartments, the component steps have been
characterized largely at the genetic level by complementation
analyses (3). In cblC, D and F groups both AdoCbl and MeCbl are
defective. However, in cblE and cblG, MeCbl is specifically
lowered, and this results from an apparent functional deficiency of
methionine synthase (4,5). Both clinically and biochemically, cblG
and E patients have similar phenotypes, displaying megaloblastic
anemia, homocystinuria, and hypomethioninemia, together
indicative of a block in the biosynthetic pathway unique to MeCbl
formation. Based on biochemical studies, it has been postulated
that cblG patients may have mutations in MS whereas the cblE
patients have defects in one of the two redox proteins that activate
MS (4). However, direct evidence from mutational analysis of the
respective genes has been lacking.
The cblG phenotype is inherited as an autosomal recessive
disorder (5). We have employed a combination of biochemical
and molecular approaches to characterize two cblG cell lines. The
first, cblG 79/96, is from a patient with severe neurological
dysfunction and homocystinuria but no megaloblastic anemia (6),
while the second, cblG WG1892, is from a patient with mental
retardation, macrocytic anemia, and homocystinuria. Both
presented with their symptoms within the first four months of life.
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Scheme 1. Postulated reaction mechanism of methionine synthase. The different reductants that are employed in the in vitro assay systems are indicated.
Heterogeneity in cblG patients is displayed at the biochemical
level (7) and has been categorized broadly into two subgroups. In
the first subclass, cblGs are indistinguishable from control cell
lines in the standard MS activity assays. In the second cblG
subclass, the catalytic activity of MS is markedly reduced (Gulati,
Rosenblatt and Banerjee, manuscript in preparation). We have
measured MS activity in fibroblast cell lines using a variety of
reductants and AdoMet, required for reductive methylation of
oxidized and inactive enzyme (Scheme 1). When artificial
reductants (such as titanium citrate or DTT) employed in the
standard assay are replaced by the physiological reducing agent,
NADPH, activity of MS is ∼50% in cblG WG1892 compared
with that in a control cell line. This information led us to suspect
that cblG WG1892, which is impaired in reductive activation but
not in catalysis, may have mutations in the activation domain
located in the carboxy-terminal half of the protein. We have
recently cloned, sequenced and mapped the human cDNA
encoding MS (8). Using SSCP analysis and sequencing, we have
detected a single base pair change resulting in a Pro1173 to Leu
mutation, and a 3 bp deletion resulting in loss of Ile881 in the
activation domain of MS of patient WG1892. In addition, we
demonstrate that the low catalytic activity observed in the cblG
79/96 patient is due to greatly reduced steady-state levels of MS
mRNA. Our data provide evidence of the MS gene being directly
involved in the pathogenesis of the cblG phenotype.
Homocystinuria is a common clinical characteristic presented
by cblG patients. Severe homocystinuria has been previously
shown to result from mutations in both cystathionine β-synthase
and methylenetetrahydrofolate reductase, two enzymes involved
either directly or peripherally, in homocysteine metabolism
(9,10). Our study presents the first evidence that MS, an enzyme
central to this metabolic circuit, is an additional genetic target for
defects leading to homocystinuria.
RESULTS
Biochemical characterization of cblG cell lines
Two cblG cell lines, WG1892 and 79/96, have been characterized
biochemically. MS in the cblG WG1892 cell line is competent in
catalysis showing an almost two-fold higher specific activity
versus a control fibroblast cell line (Table 1). However, an
impairment in the reductive activation cycle is unmasked when
Figure 1. Northern blots of cblG and control cell lines probed with either MS,
GAPDH or Huntington’s disease cDNA fragment. Lanes 1 and 4 represent
control fibroblast cell lines, the other two are from cblG patient cell lines: 79/96
(lane 2), WG1892 (lane 3). The autoradiogram with the MS probe was
developed after a 3-week exposure to maximize signal in lane 2.
the physiological NADPH-driven reducing system is employed
to activate MS, with approximately 50% of the activity seen in the
patient versus a control cell line. In contrast to cblG WG1892,
cblG 79/96 exhibits less than 1% of the activity seen with control
cell lines under all conditions employed, including high con-
centrations of reducing agents (data not shown).
Northern analysis of methionine synthase mRNA in
cblG cell lines
Steady-state levels of MS in cblG and control cell lines were
compared by Northern analysis. As shown in Figure 1, MS
mRNA levels in cblG WG1892 (lane 3) were comparable to, and
perhaps even slightly higher than in the controls (lanes 1 and 4),
but barely detectable in cblG 79/96 (lane 2) even after prolonged
exposure. In contrast, the GAPDH and Huntington’s disease gene
mRNA levels were comparable in all cell lines, ruling out lack of
mRNA integrity as an explanation for the extremely low level of
MS-specific RNA in the cblG 79/96 patient cell line.
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Table 1. Methionine synthase activity in control and patient cell lines
Cell line Specific activity* Specific activity % Holo-enzyme
TiC/-B12 TiC/+B12 NADPH/-B12
Control 157 ± 6 224 ± 1 35 ± 2 70
cblG 1892 369 ± 29 446 ± 31 17 ± 2 83
*Specific activity is expressed as pmol methionine/min/mg protein at 37C. Assays were performed in duplicate.
Table 2.  Description of PCR primers employed in this study
Primer Sequence
P1-S* 5′-ATGAGGATGATGGTGACGACTACAGC-3′
P2-A 5′-AAATCTTCCCCACAGCAAAATA-3′
P3-S 5′-ACATGTCACCCGCGCTCCAAGACCTGTC-3′
P4-A 5′-TCGACAGGGCCATTTCTCCACTCATC-3′
P5-S 5′-TCCGAGGAATGGAAGCCATTCGAGAAGC-3′
P6-A 5′-AGTTAGTCTGTATCATATCCCAAAATGG-3′
P7-S 5′-CCGAGAACTGTGGGCCTACTGTG-3′
P8-A 5′-GGTCGGGCTGGCTGGGGTA-3′
P9-S 5′-GGAGGAGCAACCACTTCAAAAAC-3′
P10-A 5′-AGCTTCTGCAGGTCATAGTCTTCAA-3′
P11-S 5′-AGCAACCACTTCAAAAACCCACAC-3′
P12-A 5′-CCACCACATTCTTGGACGCG-3′
P13-A 5′-CGCGTCCAGGACATGGACA-3′
*S and A refer to sense and antisense respectively.
SSCP and nucleotide sequencing-based detection of mutations
and polymorphisms in the methionine synthase cDNA
We have employed two complementary methods to detect
mutations in cblG WG1892. In the first approach, SSCP analysis
was used to detect single base changes in the MS cDNA.
Seventeen overlapping primer pairs spanning the MS ORF were
employed covering 100% of the coding sequence. In the second
approach, MS cDNA from cblG WG1892 was amplified in two
fragments spanning the 5′- and 3′-halves respectively by RT–
PCR (see Table 2 and Materials and Methods for primer
descriptions). The resulting products were subcloned, and the
insert containing the 3′-half of the gene was sequenced.
Several variant conformational polymorphisms were observed in
one of the amplicons shown in Figure 2. One of the control cell lines
(lane 2) is homozygous, whereas the other three [representing one
control (lane 1) and two cblG patients, cblG WG1892 (lane 3) and
cblG WG1765 (lane 4)] are heterozygous. Anomalously migrating
bands were excised from the gel and sequenced. Two of the
mutations are CpG changes, consistent with methylation-derived
transitions. The heterozygosity in the control and one of the cblG cell
lines (WG1765), which exhibit identical banding patterns, is due to
two silent mutations: 3862C to T and 3778C to A (nucleotide
numbering is based on the DNA sequence in reference 8 that
contains 286 bp upstream of the start codon). Both these changes
occur in the wobble position of the respective codons. The
anomalously migrating pair of bands in cblG WG1892 is due to a
3804C to T transition, which results in the codon for Pro1173 being
Figure 2. SSCP analysis of control and cblG cell lines. Lanes 1 and 2 represent
control cell lines, lanes 3 (cblG WG1892) and 4 (cblG WG1765) represent
patient cell lines.
changed to Leu. The complete cDNA has been analyzed by the
SSCP method, and only the ProLeu mutation described here has
been detected in this patient. A third likely polymorphism was
detected by SSCP analysis at the 5′ end of the cDNA (data not
shown). This resulted from a GA transition at nucleotide 468, and
resulted in Arg61 changing to Lys.
The 3804C to T transition destroyed an MspI restriction site and
permitted convenient confirmation of the Pro1173 to Leu
mutation by RT–PCR. The uncut PCR product (Fig. 3, lanes 1–3)
is 359 bp long. In control DNA, this fragment has two MspI sites
which results in cleavage into three bands (183, 124, and 52 bp
in length) which are observed (lanes 4–5) following restriction
digestion. In the patient, who is heterozygous for the mutation,
two different sets of digestion products are expected. The normal
allele produces the same three fragments as the controls, whereas
the mutant allele, missing one of the MspI sites, generates two
fragments that are 307 and 52 bp long. Hence, four bands are
observed upon digestion (lane 6). In the last lane, one of the bands
from the SSCP gel (Fig. 3, lane 3), carrying the C to T mutation
in a homozygous state, was excised, amplified and subjected to
resriction digestion. Only two bands were observed, as predicted.
A similar approach was employed to examine the prevalence
of this mutation in the genomic DNA from 160 control DNA
samples. Since the PCR product generated by the previously
described primer pair spans an intron (Baker and Brody,
unpublished data), a second set of primers, P7-S and P8-A (Table
2), were constructed to amplify a region of 183 bases spanning the
mutation, and avoiding the intron. The 3804C to T transition
mutation was not detected in any of the controls.
Eight clones containing the 3′ half of the MS gene (between
nucleotides 2113 and 4086) from cblG WG1892 were analyzed. An
800 bp PCR product spanning the 3804C to T transition mutation
was amplified from each of these clones and subjected to MspI
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Figure 3. Confirmation of C to T mutation in cblG WG1892 by restriction
digestion with MspI. PCR products were amplified as described in Materials
and Methods and separated on a 4% agarose gel. The lane at the far left has
molecular weight standards. Lanes 1–3 have uncut DNA from controls (lanes
1 and 2) and patient (lane 3) cell lines. MspI digested DNA was separated in
lanes 4–7, with DNA from controls (lanes 4, 5) and patient (lane 6). Lane 7 has
homozygous DNA from the SSCP gel (Fig. 2, lane 3, band 2 from top) which
was excised, reamplified and digested with MspI.
Figure 4. Nucleotide sequence analysis showing the 3 bp deletion (of AAT) in
cblG WG1892.
digestion. Of these, three did not harbor the 3804C to T transition
mutation. DNA from these three clones were subjected to double
stranded nucleotide sequencing. A 3 bp deletion (∆2926A–2928T)
was detected (Fig. 4). This mutation resulted in an in-frame deletion
of Ile881 from the human sequence. In addition, this experiment
confirmed that the ∆Ile881 and Pro1173Leu mutations are on
different chromosomes. The Ile deletion mutation was confirmed
using a mutation-specific PCR assay (described in Materials and
Methods). In addition, it was not detected in the 12 controls that were
screened (data not shown).
Modelling of the Pro1173Leu and ∆Ile881 mutations
in the activation domains of MS
Pro1173 (in the human sequence) is conserved in the human,
C.elegans and E.coli methionine synthases (8). Recently, the
crystal structure of the AdoMet binding domain of the E.coli MS
has been determined (11). Two residues, arginine and alanine, that
immediately flank the mutated proline make direct contacts to
AdoMet. The β carbon of Pro1135 (corresponding to Pro1173 in
the human sequence) is in Van der Waal’s contact with C2 of the
adenine ring of AdoMet (Fig. 5A). Replacement of a rigid proline
by a flexible leucine in this position at the active site is expected
to be detrimental.
Ile881 in the human sequence is replaced by a valine in both the
E.coli and C.elegans sequences. It lies within a region of the
protein where the primary sequence is not well conserved across
organisms (8). The crystal structure of the cobalamin binding
domain of the E.coli MS (12) reveals that the homologous Val855
lies within a β-sheet (IIβ5), which contributes to the protein wall
surrounding the nucleotide tail, dimethylbenzimidazole (Fig.
5B). Truncation of the β-sheet resulting from deletion of the
corresponding Val855 could lead to structural perturbations in
this region. It is not obvious from the structure why such an
alteration would specifically impair reductive activation.
Alternatively, it is possible that this deletion leads to inactive
enzyme, and that the biochemical phenotype of cblG WG1892 is
due to the Pro1173 to Leu mutation.
DISCUSSION
A number of lines of evidence have pointed to impairments in MS
as the basic defect in cblG patients. MS catalyzes a transmethylation
reaction in which successive methyl group transfers from
CH3-H4folate to cob(I)alamin to homocysteine lead to the products,
H4folate and methionine (Scheme 1). Due to the superreactivity of
the intermediate, cob(I)alamin, oxidation competes with remethyla-
tion, and over time, the enzyme accrues in an oxidized and inactive
state. For reentry into the catalytic cycle, a source of reducing
equivalents and AdoMet, as a methyl group donor, are required.
Under in vitro assay conditions, the requirement for reducing
equivalents is met by DTT/OHCbl or titanium citrate. The
physiological reducing system can utilize NADPH as the ultimate
source of electrons, and with the participation of two redox proteins,
can activate MS (13). This activity can be exploited under in vitro
assay conditions using cell extracts, where MS and the two
redox-active proteins are all present (13).
We have employed a combination of these assay methods to
localize defects that are specific to the reductive activation cycle.
MS in one of the cell lines, cblG WG1892, has such a biochemical
phenotype, being impaired in reductive activation but robust in
catalysis (Table 1). These data suggested that, at the molecular
level, mutations might be present in the 3′-half of the gene
encoding the B12- and AdoMet-binding domains involved in
reductive activation. CblG 79/96 on the other hand displays very
low levels of MS activity. In this cell line, one or more mutations
affecting catalysis, transcription, or stability of either the message
or the protein could explain the reduced enzyme activity.
Northern analysis revealed a greatly diminished level of MS
mRNA in cblG 79/96 accounting for its biochemical phenotype.
In contrast, the level of MS mRNA in cblG WG1892 is
comparable to that of control cell lines (Fig. 1). In this patient, two
mutations were found in trans in the activation domains of the
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Figure 5. Location of the analogous mutated residues in the three dimensional
structures of E.coli MS domains. (A) Active site structure of the AdoMet-bind-
ing domain of E.coli MS showing Van der Waal’s contacts between Pro1135
and the bound AdoMet. The flanking and conserved arginine and alanine
residues are also indicated. (B) Cobalamin-binding domain of MS showing
interactions between the protein and the lower face of the cofactor. Location of
Val855, corresponding to the deleted Ile881 in the human sequence, is indicated
in black in the middle of the β sheet, IIβ5. The α helices downstream of the
cofactor (IIα5 and IIα6) are labeled, and bound MeCbl is indicated by the ball
and stick display.
A
B
enzyme, consistent with the biochemical data. A single base
transition mutation resulting in a Pro1173 to Leu change in the
AdoMet-binding domain was detected by SSCP analysis. The
second mutation, a 3 bp deletion resulting in loss of Ile881 in the
B12-binding domain was detected by nucleotide sequence
analysis. The primers (P9-S and P10-A) spanning this region
resulted in a 331 nucleotide-long amplicon. It is likely that the
relatively long length of the PCR product precluded detection of
this mutation by SSCP analysis.
Based on the high degree of homology between the human and
E.coli methionine synthases [55% identical (8)], we predict that
the modular organization of the two enzymes will be similar. The
E.coli enzyme has been shown to be a three-domain protein, with
the substrates, cobalamin, and AdoMet binding to the N-terminal,
middle, and C-terminal domains respectively (14,15). The crystal
structures of the cobalamin (12) and AdoMet (11) binding
domains of the bacterial protein have been determined. While the
proline residue is conserved in the E.coli, C.elegans and human
MS sequences, Ile881 in the human sequence is substituted by
valines in the other two.
The homologous proline residue in the bacterial MS is in Van
der Waal’s contact with the bound AdoMet (11). Its role, along
with two proximal prolines (two and five residues downstream),
is postulated to be to stiffen the loop thereby fixing the orientation
of the backbone (11). The flanking and conserved arginine and
alanine residues make direct docking interactions that have been
identified as being important for AdoMet binding. The three
dimensional structure of this domain provides a structural
rationale for the detrimental effect of this mutation and provoca-
tive evidence for the involvement of the AdoMet-binding domain
in electron transfer from the proximal redox partner to MS.
Isoleucine at position 881 in the human sequence corresponds
to Val855 in the E.coli sequence and resides in the cobalamin-
binding domain. The three dimensional structure of this domain
(12) reveals that Val855 is in the middle of a six residue long
β-sheet (IIβ5), which together with the adjoining α helix (IIα5)
forms one of the walls around the buried dimethylbenzimidazole
moiety of the bound cobalamin (Fig. 5B). Helix, IIα5, then leads
into helix IIα6, which connects to the AdoMet binding domain.
Deletion of the corresponding Val855 would lead to contraction
of the β-sheet potentially creating structural deformations in the
protein wall cupping the cofactor tail. This could either impair
cofactor binding or affect domain rearrangement that is expected
to occur as the protein switches from the catalytic to the activation
mode. It is interesting that a mutation in this region that is distal
to the corrin ring is associated with a biochemical phenotype in
which reductive activation is specifically impaired. It is possible
that the ∆Ile881 mutation results in inactive enzyme, and that the
biochemical phenotype of the cblG WG1892 patient cell line
stems entirely from the Pro1173 to Leu mutation. Characteriz-
ation of the recombinant mutant human enzymes in the future will
permit direct evaluation of this issue.
Mutations in methylenetetrahydrofolate reductase and cystathio-
nine β-synthase, both involved in homocysteine metabolism, have
been described (9,10). These mutations result in homocystinuria in
homozygous affected patients. Similarly, dysfunction of MS has
been implicated in homocystinuria inherited as an autosomal
recessive inborn error of metabolism. Our results now furnish
direct evidence for the complicity of MS in homocystinuria.
MATERIALS AND METHODS
Cell culture
Fibroblast cell line cblG WG1892 was purchased from the
Repository for Mutant Human Cells, Montreal Children’s
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Hospital. Control cell lines and cblG 79/76 were available in our
laboratories. The control DNAs were a subset of those described
previously (16). Cultures were maintained in Eagle’s minimum
essential medium plus nonesssential amino acids (Sigma), and
supplemented with 10% (v/v) fetal bovine serum (Calbiochem).
Cells were grown to confluency on ten 150 mm petri dishes, and
harvested using a cell scraper. The cells were pelleted at
1200 r.p.m. for 15 min, washed 2 times with phosphate buffered
saline and frozen at –80C.
Methionine synthase assay
Approximately 108 cells were resuspended in 1 ml of 100 mM
phosphate buffer, pH 7.4, containing 0.25 M sucrose. The cell
membranes were disrupted by sonication on ice using the
miniprobe (power output setting of 4) and the following cycle:
20 s pulse, 1 min pause, repeated five times. The homogenate was
centrifuged at 4C, at 12 000 × g for 60 min. The resulting
supernatant was aliquoted and stored at –80C. The in vitro
anaerobic assays were performed essentially as described
previously (17) at 37C for 75 min. When the physiological
activation system was employed to measure MS activity, 1 mM
concentration of NADPH was used.
Northern blots
RNA was isolated from approximately 106 cells from control and
patient cell lines using RNAStat-60, following the procedure
recommended by the vendor (Tel-Test ‘B’ Inc, Texas). The RNA
was quantitated spectrophotometrically, and ∼10 µg RNA/lane
was loaded on a 1% formaldehyde agarose gel. The RNA was
transferred from the gel to a Hybond N+ membrane (Amersham).
A 2.2 kb BglI fragment from the coding region of the human MS
was end-labeled with [32P] γ-dCTP (3000 Ci/mol) and 3 ml
(containing ∼106 counts/ml) of Church and Gilbert hybridization
solution and used to probe the northern blot. Hybridization was
conducted overnight at 65C, and the membrane was washed
three times with 2× SSC/10% sodium dodecyl sulfate at the same
temperature. For hybridization to control probes the membrane
was later stripped by boiling in 0.1× SSC, 0.1% SDS for 10 min,
and reprobed with human GAPDH cDNA and a 670 bp fragment
from Huntington’s disease gene cDNA.
SSCP analysis
RNA isolated as described above was employed as template for
first strand cDNA synthesis. The reaction mixture containing 1 µg
of RNA in DEPC-treated water (total volume 13 µl) and 1 µl of
1 µg/µl of oligo dt (from Invitrogen) was mixed and heated at 65C
for 10 min, followed by incubation on ice for 2 min. Then the
following solutions were added: 2 µl of 10× synthesis buffer (Gibco
BRL), 2 µl of 0.1 M DTT, and 1 µl of 10 mM dNTP (Amersham).
The sample was mixed by vortexing, spun down and incubated at
42C for 2 min before 1 µl of Reverse Transcriptase (BRL) was
added. Incubation was continued at 42C for 30 min, the sample
was centrifuged and placed on ice. RNaseH (1 µl) was added and
the mixture was incubated for 10 min at 42C. The sample was
cooled on ice, then stored at –20C.
First strand material was amplified for SSCP. Seventeen primer
pairs were employed to completely span the open reading frame.
The sequences of these primers are available from the authors on
request. Primers P1-S and P2-A generated an amplicon harboring
the C3804T mutation. Radiolabeled dCTP (α-dCTP, 3000
Ci/mol) was added to the PCR mixture. The following temperature
cycling conditions were employed using the touch down program:
95C for 2 min followed by 94C for 30 s, annealing/extension at
67C for 40 s, with the annealing temperature decreasing by
1.1C/cycle for 12 cycles. The next 35 cycles used the following
conditions: 94C for 30 s, 54C for 30 s, 72C for 30 s.
PCR products were diluted ten-fold with loading buffer (95%
formamide, 10 mM NaOH, 0.25% bromophenol blue) prior to
use. The heat denatured PCR products (95C for 5 min followed
by incubation on ice for 3 min) were separated on a 0.5× MDE
(FMC) sequencing gel at ambient temperature. Bands of interest
were excised from the sequencing gel and reamplified using the
conditions described above. The PCR products were purified
using the Wizard PCR purification system (Promega) and
subjected to fluorescent nucleotide sequencing on an ABI 377
Automated Sequencer.
Mutation identification by nucleotide sequence analysis
RT–PCR was carried out using Advantage Klen Taq DNA
Polymerase (Clontech Inc.) from first strand cDNAs of two
controls, HS-68 and MRC-5, and two clbG cell lines, WG1892
and 79/96. The amplifications produced ∼2 kb DNA fragments
that spanned the 5′ half and 3′ halves of the gene respectively, and
overlapped by 265 bp. The primer sets used for these two PCR
reactions were P3-S/P4-A and P5-S/P6-A respectively. Since the
enzymatic assay data suggested that mutations in cblG WG1892
are likely to be in the C-terminal reductive activation domains,
clones containing the 3′ half of the gene were further studied.
Semi-nested PCR was performed using 1 µl of 100-fold diluted
PCR product containing the 3′ half of the gene by using
3NGSP1/P6-A [Table 2 and Table in reference (8) for primer
description] and the amplified DNA fragments were cloned into
the T/A cloning vector, pCR2.1 (Invitrogen Inc.). Eight clones
were then used as templates for PCR amplification of a 800 bp
fragment (using primers P15F/ P6-A, Table 2; ref. 8) containing
the C3804T transition mutation (Pro1173Leu) previously
detected by SSCP in a heterozygotic state. To distinguish the
known allele from the unknown allele the 800 bp fragments were
digested with MspI and separated on a 2% agarose gel. Three
clones that did not have the C3804T mutation were completely
sequenced on both strands using the automated sequencing
facility at Fox Chase Cancer Center.
Confirmation of the Ile deletion mutation
To confirm Ile881 deletion in genomic DNA and to examine its
prevalence in control samples, a mutation specific primer assay
system was utilized. Two primers flanking the mutation site,
P-11S and P12-S (Table 2) were synthesized. A third primer,
specific for the mutant allele, P13-A, was also synthesized. This
primer is designed to be complementary to the mutant sequence
and will contain a mismatched 3′ terminus when annealed to wild
type DNA. Genomic DNA was PCR amplified in a reaction
containing all three primers. Reaction conditions were as
previously described except that 5-fold less of the flanking
mutation specific primer, P13-A was added. The outside primer
pair amplifies a 95 bp fragment in all samples. If the mutant
sequence is present an additional fragment of 79 bp is observed.
PCR products were resolved on 10% acrylamide minigels in 0.5×
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TBE buffer. The control cell lines employed in this study have
been described previously (16).
ACKNOWLEDGEMENTS
We are very grateful to Profs. Martha Ludwig and Rowena
Matthews at the University of Michigan for sharing the coordi-
nates of the AdoMet binding domain of MS prior to publication.
We acknowledge Tzanko Dukov at the University of Nebraska
for his help with structure analysis, Christianne Robbins at the
NCHGR core facility for performing nucleotide sequencing, Dan
Tagle at NCHGR for the Huntington’s Disease gene fragment,
and Dr E. A. Kvittingen at Rikshospitalet, Oslo, for making
fibroblast cell line 79/96 available to Dr Fowler. This work was
supported by the National Institutes of Health (DK45776 to R.B),
Center for Biotechnology, UNL (to R.B) and the Pew Charitable
Trust (to Y.L. and W.K.).
ABBREVIATIONS
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NOTE ADDED IN PROOF
The Ile881 deletion mutation in WG1892 has been found inde-
pendently by Dr R.Rozen, Montreal Children’s Hospital (per-
sonal communication; Hum. Mol. Genet. 5, 1867–1874).
